Opko Health, Inc. (NASDAQ:OPK) has earned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $16.43.

A number of brokerages have recently weighed in on OPK. BidaskClub upgraded Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a report on Friday, June 16th. Jefferies Group LLC restated a “hold” rating and issued a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a report on Thursday, August 10th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a report on Friday, July 21st. Finally, Barrington Research increased their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, July 18th.

Opko Health (OPK) traded down 1.45% during midday trading on Friday, hitting $6.13. 2,971,959 shares of the company traded hands. The company’s market cap is $3.43 billion. The stock has a 50 day moving average price of $6.24 and a 200-day moving average price of $6.97. Opko Health has a 12-month low of $5.85 and a 12-month high of $12.15.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm’s quarterly revenue was down 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.02 EPS. Analysts expect that Opko Health will post ($0.20) EPS for the current year.

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was purchased at an average price of $6.43 per share, with a total value of $1,286,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $19,733,354.93. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased 1,050,300 shares of company stock worth $6,671,904 in the last 90 days. 40.19% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Opko Health by 1.1% in the second quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock valued at $175,151,000 after acquiring an additional 296,757 shares during the period. BlackRock Inc. boosted its position in shares of Opko Health by 1.1% in the second quarter. BlackRock Inc. now owns 22,901,261 shares of the biotechnology company’s stock valued at $150,689,000 after acquiring an additional 255,976 shares during the period. State Street Corp boosted its position in shares of Opko Health by 3.9% in the second quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock valued at $74,671,000 after acquiring an additional 422,203 shares during the period. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management boosted its position in shares of Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock valued at $40,489,000 after acquiring an additional 1,944,549 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Opko Health by 7.9% in the first quarter. Geode Capital Management LLC now owns 2,889,059 shares of the biotechnology company’s stock valued at $23,111,000 after acquiring an additional 210,736 shares during the period. 22.46% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/09/opko-health-inc-opk-given-consensus-recommendation-of-buy-by-brokerages.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.